How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,528 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

27821. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. (Abstract)

Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Few studies evaluate the effect of topical corticosteroids on thermal sensation and in alleviation of itch produced by intradermal injection of histamine. We evaluated the antipruritic effect of hydrocortisone (1% and 2.5%) on histamine-induced itch and sensory effects by measuring itch magnitude, itch duration and thermal thresholds using a computerized thermal sensory analyzer (TSA). This was a double-blind (...) recorded. In comparison to placebo, 2.5% hydrocortisone significantly (p = 0.03) reduced itch duration from 12.6 +/- 11.0 min (mean +/- SD) to 8.6 +/- 8.2 min (the reducing rate was 32%) as well as itch magnitude (at minutes 3, 6, 7 and overall). Placebo, 1% and 2.5% hydrocortisone significantly altered (p <0.05) the cold sensation threshold. No treatment altered cold or heat pain thresholds. These data suggest that topical application of 2.5% hydrocortisone may be significantly beneficial

2001 Skin pharmacology and applied skin physiology Controlled trial quality: uncertain

27822. Perioperative microbiologic profile of the conjunctiva in photorefractive keratectomy. (Abstract)

) developed a peripheral corneal infiltrate. The corneal infiltrate healed completely without sequelae using antibiotic and corticosteroid therapy.The use of therapeutic soft contact lenses after PRK with either topical tobramycin 0.3% or ofloxacin 0.3% were well tolerated. However, perioperative positive conjunctival cultures were relatively frequent and prophylactic antibiotics should be used in the setting of an epithelial defect and therapeutic soft contact lens following PRK. (...) contact lens, and compared the effect on ocular bacterial colonization of prophylactic administration of topical tobramycin 0.3% versus ofloxacin 0.3%.Forty-three consecutive eyes from 37 patients underwent PRK for myopia or myopic astigmatism. Eyes were assigned randomly to prophylactic antibacterial treatment with either topical ofloxacin 0.3% or tobramycin 0.3%, applied prior to surgery and three times daily after surgery until therapeutic soft contact lens removal. Material from the conjunctival

2001 Journal of Refractive Surgery Controlled trial quality: uncertain

27823. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. (Abstract)

of a topical skin lipid mixture in the treatment of ICD, ACD and AD. 580 consecutive patients suffering from ICD, ACD or AD were treated with a skin lipid mixture containing ceramide-3 and patented nanoparticles. Patients received the lipid mixture alone or in combination with topical corticosteroids until clearance or for 8 weeks. Both treatment groups statistically improved all parameters considered at week 4 and 8 as compared to baseline. Between the 2 treatment groups, there was a statistically

2001 Contact dermatitis Controlled trial quality: uncertain

27824. Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial. (Abstract)

Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial. Budesonide is an inhaled corticosteroid with high topical potency and low systemic activity recommended in the treatment of chronic asthma.This study was conducted to determine the efficacy and safety of inhaled budesonide via a breath-activated, multi-dose, dry-powder inhaler.Multicenter randomized parallel-group, placebo-controlled, double-blind, clinical trial.Multicenter

2001 São Paulo medical journal = Revista paulista de medicina Controlled trial quality: predicted high

27825. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. (Abstract)

A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Leukotriene receptor antagonists are recommended for the treatment of asthma, and have proved anecdotally successful even in atopic dermatitis. Standard treatments of atopic dermatitis are often unsatisfactory. Accordingly, we compared montelukast, 10 mg/day, with a combined regimen (orally administered cetirizine and clarythromycin, topical corticosteroids and hydrating

2001 European journal of dermatology : EJD Controlled trial quality: uncertain

27826. Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. (Abstract)

Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. Atopic dermatitis is a chronic, relapsing condition affecting up to 14% of the population in Western countries. Topical corticosteroids are the mainstay of treatment. Triamcinolone acetonide, a corticoid of intermediate potency, has proven useful in the treatment of atopic dermatitis.To evaluate the effectiveness of a triamcinolone acetonide-laurocapram combination in the treatment

2001 International journal of dermatology Controlled trial quality: uncertain

27827. Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. (Abstract)

Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. High-dose inhaled corticosteroids (ICS) have been associated with the same side-effects as oral corticosteroids. Beclomethasone dipropionate (BDP) and budesonide (BUD) in doses greater than 2000 microg/day are used regularly in severe asthma, despite the fact that safety and efficacy data at such high doses are limited. Fluticasone propionate (FP) has been promoted as being (...) was based on morning peak expiratory flow measurements recorded by patients on daily record cards, while determination of safety was based on a number of endpoints including changes in bone turnover indices, the incidence of topical side-effects and assessments of quality of life.It was shown that patients who were switched to FP, but not those continuing with BDP or BUD, had significant increases in levels of morning serum cortisol and the urine cortisol:creatinine ratio while maintaining asthma

2001 Respirology (Carlton, Vic.) Controlled trial quality: uncertain

27828. Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. (Abstract)

of hemoglobin desaturation and respiratory movement/arousals also decreased more in the fluticasone group. Changes from baseline in tonsillar size, adenoidal size, and symptom score were not significantly different between groups.Nasal fluticasone decreased the frequency of mixed and obstructive apneas and hypopneas, suggesting that topical corticosteroids may be helpful in ameliorating pediatric obstructive sleep apnea.

2001 The Journal of pediatrics Controlled trial quality: uncertain

27829. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. (Abstract)

Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Calcipotriol and corticosteroids are established topical antipsoriatics. Previous studies have shown that combined therapy with calcipotriol and betamethasone dipropionate was more effective than monotherapy. In the present study, a recently developed combination product of calcipotriol and betamethasone dipropionate was compared with both monotherapies and the vehicle.Twenty

2001 Dermatology (Basel, Switzerland) Controlled trial quality: uncertain

27830. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. (Abstract)

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Vehicle-controlled studies have demonstrated the efficacy and safety of tacrolimus ointment for patients with atopic dermatitis.This study was undertaken to compare 0.03% and 0.1% tacrolimus ointment with 0.1% hydrocortisone-17-butyrate ointment, a midpotent to potent topical corticosteroid, in the treatment of adult patients with moderate-to-severe atopic

2002 The Journal of allergy and clinical immunology Controlled trial quality: uncertain

27831. Flow cytometric assessment of clearance and relapse characteristics in psoriasis vulgaris after treatment with weekly clobetasol lotion under hydrocolloid occlusion versus twice-daily clobetasol ointment. (Abstract)

possible that the outcome in the treatment of more extensive psoriatic lesions might be different, the present study suggests that the robust clinical efficacy of the treatment with a topical corticosteroid under hydrocolloid occlusion is not associated with a rebound phenomenon.Copyright 2002 S. Karger AG, Basel (...) was performed on epidermal single cell suspensions prepared from 3-mm punch biopsies taken from 15 patients with psoriasis vulgaris before therapy, at clearance and 6 weeks after clearance. After treatment both therapy regimens resulted in substantial changes of all flow cytometric parameters, but clearance was induced earlier in the corticosteroid under hydrocolloid occlusion-treated group. With respect to the relapse phase no difference was observed between both treatments. Although it is remotely

2002 Skin pharmacology and applied skin physiology Controlled trial quality: uncertain

27832. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. (Abstract)

Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. Psoriasis is a chronic relapsing skin disorder that affects about 2% of the U.S. population and involves the scalp approximately 50% of the time. Topical corticosteroids, including betamethasone valerate, have been used effectively in the treatment of corticosteroid-responsive dermatoses of the skin and scalp. Betamethasone valerate (...) (BMV) in foam vehicle (Luxiq) is designed to improve patient compliance with topical therapy. Superior efficacy over a BMV lotion preparation has been demonstrated with twice-daily use. Even greater compliance would be expected if the drug is effective with once-daily application.To compare the efficacy of the betamethasone valerate foam (Luxiq) in the treatment of scalp psoriasis following once-daily versus twice-daily dosing.Seventy-nine patients with moderate to severe scalp psoriasis from seven

2002 Journal of cutaneous medicine and surgery Controlled trial quality: uncertain

27833. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. (Abstract)

pollen were allocated to double-blinded clustered IT with a depot birch pollen extract (Betula verrucosa) or placebo injections. Seven patients in each group had concomitant self-reported seasonal asthma. Treatment was conducted as a clustered regimen and was performed in a specialist unit. Symptom scores from nose, eyes, and lungs, and use of oral and topical antihistamines, beta-2-agonists, and oral corticosteroids were recorded daily during the season of 2000. Sensitivity to allergen provocation

2002 Allergy Controlled trial quality: uncertain

27834. Placebo-controlled, randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for the treatment of patients with hyposmia/anosmia. (Abstract)

of at least 2 steps in the butanol odor threshold test following open treatment for 10 days with oral and nasal corticosteroids. Forty patients were included: 20 were randomized to treatment with fluticasone propionate, 10 to placebo and 10 others as controls. The topical treatment was continued for 6 months.The 3 groups showed similar improvements in their sense of smell after the initial 10-day treatment with combined oral and nasal corticosteroids. Patients who continued the local treatment maintained (...) the same level of improvement throughout the study, whether or not they had been given nasal corticosteroids or placebo. We found no significant differences between the treatment groups.In patients with anosmia/hyposmia partly caused by local inflammation, no further improvement in the olfactory threshold is achieved by continuing with a topical intranasal glucocorticoid after an initial combined topical and systemic glucocorticoid treatment.

2003 Acta oto-laryngologica Controlled trial quality: predicted high

27835. The effect of budesonide on the cytokine pattern in patients with perennial allergic rhinitis. (Abstract)

The effect of budesonide on the cytokine pattern in patients with perennial allergic rhinitis. A T(H)2-polarized cytokine pattern has been demonstrated in allergic rhinitis. Budesonide represents an effective topical corticosteroid in the management of allergic rhinitis.To evaluate cytokine pattern and symptoms in patients with perennial allergic rhinitis before and after treatment with intranasal budesonide.All patients received budesonide aqueous nasal spray or placebo for 2 weeks. The study

2003 Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology Controlled trial quality: uncertain

27836. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. (Abstract)

A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Topical antiinflammatory medications such as inhaled corticosteroids are recommended for therapy of asthma, but no formulation suitable for administration to infants and young children is available in the United States.This was a 12-week, multicenter, double-blind, randomized, parallel-group study comparing the efficacy (...) and safety of four dosing regimens of bude-sonide inhalation suspension (BIS) or placebo in 480 asthmatic infants and children (64% boys), ages 6 months to 8 years, with moderate persistent asthma. Approximately 30% of children were previously on inhaled corticosteroids that were discontinued before the study. Active treatments were comprised of BIS 0.25 mg once daily (QD), 0.25 mg twice a day (BID), 0.5 mg BID, or 1.0 mg QD. Efficacy was assessed by twice daily recording at home of asthma symptom scores

1999 Pediatrics Controlled trial quality: uncertain

27837. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. (Abstract)

Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Vernal keratoconjunctivitis (VKC) is a severe though transient form of ocular allergy, predominant in young males, which requires careful management. Corticosteroids are effective but also cause serious topical side-effects in the eye, such as glaucoma and cataracts. The safer, mast cell stabilizing anti-inflammatories (commonly sodium cromoglycate

1999 Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology Controlled trial quality: uncertain

27838. Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. (Abstract)

Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. A single high dose of inhaled corticosteroid (ICS) can increase airway caliber in children with asthma attacks and laryngitis subglottica. Presumably the effect is due to the vasoconstrictive and antiedematous properties of topical steroids. Enlarged vessels have been suggested to play a role in the pathophysiology of exercise-induced bronchial obstruction (EIB). To investigate this, we evaluated

2001 Pediatric pulmonology Controlled trial quality: uncertain

27839. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. (Abstract)

Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Allergen specific nasal challenge (ASNC) is an optimal model to study the pathophysiologic mechanisms sustaining allergic inflammation, particularly the adhesion molecules promoting cellular infiltration of nasal mucosa. Topical corticosteroids have been accepted as a highly effective anti-inflammatory therapy for allergic rhinitis.The aim of this double-blind, randomized, placebo-controlled study

2001 Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology Controlled trial quality: uncertain

27840. Repetitive usage testing with budesonide in experimental nickel--allergic contact dermatitis in individuals hypersensitive to budesonide. (Abstract)

Repetitive usage testing with budesonide in experimental nickel--allergic contact dermatitis in individuals hypersensitive to budesonide. Contact allergy to topical corticosteroids on patch testing is well recognized, but the clinical significance is uncertain.To determine the clinical relevance of contact allergy to topical corticosteroids.Seven patients hypersensitive to both budesonide and nickel repeatedly applied budesonide, betamethasone valerate or the common base for both (...) corticosteroids to areas of experimentally induced nickel dermatitis. Nineteen controls allergic to nickel, but not budesonide went through the same procedure.Seventy-one per cent of the budesonide-allergic individuals experienced distant ipsilateral flares of toxicoderma-like eruptions, in addition to a severe deterioration of the experimental dermatitis treated with budesonide, i.e. increased erythema, and abundant papules and vesicles. The areas of dermatitis in all of the 19 controls healed

2001 The British journal of dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>